Abstract
Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
